AKBA:NSD-Akebia Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 12.15

Change

-0.01 (-0.08)%

Market Cap

USD 1.58B

Volume

0.99M

Average Target Price

USD 14.88 (+22.43%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-05-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-18.46 (-6.48%)

USD73.88B 49.39 37.03
REGN Regeneron Pharmaceuticals, Inc

-24.70 (-4.33%)

USD64.13B 28.64 21.76
SGEN Seattle Genetics, Inc

-4.04 (-2.59%)

USD26.26B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.30 (+1.28%)

USD22.70B 9.81 8.43
INCY Incyte Corporation

-0.69 (-0.69%)

USD21.60B 47.64 35.20
MRNA Moderna, Inc

-11.29 (-16.36%)

USD21.42B N/A N/A
GMAB Genmab A/S

+1.22 (+4.16%)

USD19.59B 52.40 5.57
BMRN BioMarin Pharmaceutical Inc

+6.23 (+6.39%)

USD17.63B 154.78 92.86
ALNY Alnylam Pharmaceuticals, Inc

-4.09 (-2.91%)

USD16.13B N/A N/A
GLPG Galapagos NV

+4.45 (+2.22%)

USD13.13B 70.13 37.04

ETFs Containing AKBA

Symbol Name Weight Mer Price(Change) Market Cap
BBC Virtus LifeSci Biotech Cl.. 1.91 % 0.79 %

-0.90 (-2.10%)

USD0.03B
IWC iShares Micro-Cap ETF 0.50 % 0.60 %

+1.92 (+2.38%)

USD0.66B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 92.25% 89% B+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 92.25% 89% B+ 95% A
Trailing 12 Months  
Capital Gain 131.87% 87% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 131.87% 87% B+ 94% A
Trailing 5 Years  
Capital Gain 47.27% 78% C+ 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.27% 77% C+ 72% C-
Average Annual (5 Year Horizon)  
Capital Gain 1.04% 51% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.04% 51% F 28% F
Risk Return Profile  
Volatility (Standard Deviation) 50.94% 42% F 21% F
Risk Adjusted Return 2.04% 52% F 31% F
Market Capitalization 1.58B 82% B- 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.00 54% F 30% F
Price / Cash Flow Ratio -6.15 53% F 78% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -55.67% 60% D- 22% F
Return on Invested Capital -49.87% 61% D- 18% F
Return on Assets -14.54% 81% B- 24% F
Debt to Equity Ratio 19.20% 55% F 66% D
Technical Ratios  
Short Ratio 8.01 29% F 15% F
Short Percent 6.84% 42% F 31% F
Beta 1.27 61% D- 40% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector